Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)
Author:
Publisher
Springer Science and Business Media LLC
Subject
Urology,Reproductive Medicine,General Medicine
Link
http://link.springer.com/content/pdf/10.1186/1471-2490-14-55.pdf
Reference45 articles.
1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 2013, 63 (1): 11-30.
2. Huggins C, Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972, 22 (4): 232-240.
3. Borgmann V, Hardt W, Schmidt-Gollwitzer M, Adenauer H, Nagel R: Sustained suppression of testosterone production by the luteinising-hormone releasing-hormone agonist buserelin in patients with advanced prostate carcinoma. A new therapeutic approach?. Lancet. 1982, 1 (8281): 1097-1099.
4. Sharifi N, Gulley JL, Dahut WL: Androgen deprivation therapy for prostate cancer. J Am Med Assoc. 2005, 294 (2): 238-244.
5. Becker LE, Birzgalis EP: Orchiectomy in the management of adenocarcinoma of the prostate. Surg Gynecol Obstet. 1966, 122 (4): 840-843.
Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer;JAMA Oncology;2024-05-01
2. Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol;Future Oncology;2024-03-15
3. Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study;European Urology Oncology;2023-12
4. Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer;Cancers;2023-10-05
5. Influence of ADT on B7-H3 expression during CRPC progression from hormone-naïve prostate cancer;Cancer Gene Therapy;2023-07-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3